JSPR vs. DCGO, AGFS, GRNA, DNA, CGEM, TARS, FDMT, BCRX, AUTL, and IMTX
Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include DocGo (DCGO), AgroFresh Solutions (AGFS), GreenLight Biosciences (GRNA), Ginkgo Bioworks (DNA), Cullinan Therapeutics (CGEM), Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), and Immatics (IMTX).
Jasper Therapeutics (NASDAQ:JSPR) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.
DocGo has a net margin of 2.98% compared to Jasper Therapeutics' net margin of 0.00%. DocGo's return on equity of 6.20% beat Jasper Therapeutics' return on equity.
Jasper Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500. Comparatively, DocGo has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
In the previous week, Jasper Therapeutics had 2 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for DocGo. Jasper Therapeutics' average media sentiment score of 0.63 equaled DocGo'saverage media sentiment score.
DocGo has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
DocGo received 15 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 83.87% of users gave Jasper Therapeutics an outperform vote while only 73.21% of users gave DocGo an outperform vote.
Jasper Therapeutics currently has a consensus price target of $64.29, indicating a potential upside of 147.63%. DocGo has a consensus price target of $7.75, indicating a potential upside of 164.51%. Given DocGo's higher possible upside, analysts clearly believe DocGo is more favorable than Jasper Therapeutics.
79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by company insiders. Comparatively, 2.7% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
DocGo beats Jasper Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Jasper Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jasper Therapeutics Competitors List
Related Companies and Tools
